Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 682.

https://doi.org/10.1182/blood-2025-682

Published: 2025

Journal Articles

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

John M. Burke, Jeff Sharman, Bertrand Anz, Richard Zuniga, Aung Tun, David Wright, Prachi Jani, Juliana Biondo, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Jose Villasboas Bisneto, Elizabeth Budde, Ian Flinn

Blood (2025) 146 (Supplement 1): 228.

https://doi.org/10.1182/blood-2025-228

Published: 2025

Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman

Blood (2025) 146 (Supplement 1): 8245.

https://doi.org/10.1182/blood-2025-8245

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Jose Villasboas Bisneto, John M. Burke, Aung Tun, Steve Liu, Jeff Sharman, Juliana Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Rona Farighi, Javier Munoz, Furhan Yunus, Ian Flinn, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2025-1807

Published: 2025

Journal Articles

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Jeff Sharman, Aung Tun, Jose Villasboas Bisneto, Ayed Ayed, Prachi Jani, Juliana Biondo, Mei Wu, Farah Hossain, Yong Mun, Vivek S. Chopra, Rona Farighi, Jamal Misleh, Shachar Peles, Ian Flinn, John M. Burke

Blood (2025) 146 (Supplement 1): 62.

https://doi.org/10.1182/blood-2025-62

Published: 2025

Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2025-3301

Published: 2025

Journal Articles

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Toby Eyre, Matthew S Davids, Jeff Sharman, Paul Barr, Catherine Coombs, Wojciech Jurczak, Koji Izutsu, Meghan Thompson, William Wierda, Ying (denise) Wang, Marisa Hill, Donald Tsai, Ching Ching Leow, Sarang Abhyankar, Paolo Ghia, Jennifer Woyach

Blood (2025) 146 (Supplement 1): 5670.

https://doi.org/10.1182/blood-2025-5670

Published: 2025

Journal Articles

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Mazyar Shadman, Ian Flinn, Moshe Levy, Steven Papish, John M. Burke, Jamal Misleh, Jennifer Cultrera, Habte Yimer, Edwin Kingsley, Charles Farber, James D'Olimpio, Nan Sun, Adam Idoine, Jeff Sharman

Blood (2025) 146 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2025-5663

Published: 2025

Journal Articles

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Blood (2025) 146 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2025-1959

Published: 2025

Journal Articles

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Anthony R. Mato, MDMSCE, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2018-99-110566

Published: 2018

Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid

Blood (2018) 132 (Supplement 1): 394.

https://doi.org/10.1182/blood-2018-99-111248

Published: 2018

Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2018-99-110847

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Jeff Sharman, MD, Shaum Kabadi, PhD MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, David J. Andorsky, MD

Blood (2018) 132 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2018-99-118848

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Jeff Sharman, MD, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Anthony R. Mato, MD MSCE

Blood (2018) 132 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2018-99-110562

Published: 2018

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD

Blood (2016) 128 (22): 1856.

https://doi.org/10.1182/blood.V128.22.1856.1856

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only